Opinion: Good riddance to bundled ‘global’ maternal care billing

A change is coming to the codes OB-GYNs use to bill for maternity care services: Starting Jan. 1, 2027, we will shift from a bundled “global obstetric payment” to a fee-for-service model. This change impacts almost every U.S. family with a pregnancy. Under the current system, families receive a bill that does not distinguish the actual prenatal and postpartum costs from labor and delivery, which makes things incredibly confusing for patients.

In fact, the bundled payment’s impacts have been widespread: It has complicated billing for patients and clinicians, limited access to care, cut back the ability to provide patients with more personalized care, and slowed progress in better understanding U.S. maternal health outcomes.

Read the rest…

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

As more Americans experiment with synthetic peptides despite warnings about their unproven benefits and potential risks, an advisory panel to the Food and Drug Administration will meet on Thursday and Friday to discuss changes that could make peptides more accessible. 

At issue is whether to allow compounding pharmacies to manufacture seven peptides that are currently designated as unsafe for them to make. The panel discussion is expected to be unusual in more ways than one. 

First, many of the newly appointed members on the panel hold what critics (including FDA staff) say are conflicts of interest. The panel roster includes several physicians who prescribe peptides to patients as well as pharmacist and Tennessee state Sen. Bobby Harshbarger, whose mother, U.S. Rep. Diana Harshbarger (R-Tenn.) has advocated for looser peptide regulations. Many of these panelists were selected by the Health and Human Services Department, FDA officials previously told STAT. 

Continue to STAT+ to read the full story…

A spatial view of tumor neoantigen recognition

Nature Biotechnology, Published online: 22 July 2026; doi:10.1038/s41587-026-03203-3

The cell-by-cell interactions between neoantigen-expressing tumor cells and tumor-specific T cells remained largely unexplored. A single-cell spatial transcriptomics framework enables mapping of neoantigen-expressing tumor cells and tumor-infiltrating T cells, as well as T cell receptor sequencing. This approach reveals distinct immune niches in the tumor microenvironment and their properties that determine tumor-specific responses.

STAT+: What is a ‘world model’? Nabla’s Alex LeBrun explains

You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. 

Every time I interview someone from an AI scribe company, I ask if it’s OK to record the interview for my notes and make a joke about the ironic situation.

Turns out, not everyone is asking, and people have started to record their daily conversations, such as first dates, without asking. “This Conversation is Being Recorded. They All Are” is the Wall Street Journal’s headline. What a hellscape.

Continue to STAT+ to read the full story…

New study supports testing of Merck’s Ebola vaccine in DRC outbreak

New data from a study in humans provides additional support to the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another species currently circulating in a rapidly expanding outbreak in the Democratic Republic of the Congo.

The new paper, published Wednesday in the New England Journal of Medicine after previously having been posted online before peer review, is one of a growing number of studies pointing to the possibility that the vaccine could be used to target the Bundibugyo species of ebolaviruses. 

Read the rest…